Iovance Biotherapeutics, Inc. Common Stock
Here’s whether Iovance Biotherapeutics, Inc. Common Stock (IOVA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.69% over 10 days); strong 1-year return of +184.9%; 3-month momentum positive (+102.3%); rising volume confirms the move (1.21x 30d avg). Concerns: RSI 73 — overbought, elevated pullback risk. Currently 0.3% off its 52-week high. Score: +6/7.
IOVA is in a confirmed uptrend, trading above both its 50-day ($4.66) and 200-day ($3.48) moving averages. With an RSI of 73.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +184.9% compares to +20.4% for SPY (beat the market by 164.5%).